NO20051159L - Preparations and Methods for the Treatment of Diseases That Incorrectly Assemble Protein Aggregation - Google Patents
Preparations and Methods for the Treatment of Diseases That Incorrectly Assemble Protein AggregationInfo
- Publication number
- NO20051159L NO20051159L NO20051159A NO20051159A NO20051159L NO 20051159 L NO20051159 L NO 20051159L NO 20051159 A NO20051159 A NO 20051159A NO 20051159 A NO20051159 A NO 20051159A NO 20051159 L NO20051159 L NO 20051159L
- Authority
- NO
- Norway
- Prior art keywords
- preparations
- methods
- diseases
- treatment
- protein aggregation
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000004845 protein aggregation Effects 0.000 title 1
- 108091034117 Oligonucleotide Proteins 0.000 abstract 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Endocrinology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Obesity (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- Psychiatry (AREA)
Abstract
Forbindelser, preparater og farrnasøytiske preparater som omfatter oligonukleotider som er i stand til å ødelegge proteinaggregeringer som er karakterisfiske for forstyrrelser med sammensetning av protein, blir beskrevet sammen med in vitro- og in vivo-fremgangsmåter for identifisering av slike oligonukleotider og fremgangsmåter for å behandle slike forstyrrelser ved administrering av slike preparater.Compounds, preparations, and farrowing preparations comprising oligonucleotides capable of destroying protein aggregates characteristic of protein composition disorders are described together with in vitro and in vivo methods for identifying such oligonucleotides and methods for treating such disorders in the administration of such preparations.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40219802P | 2002-08-07 | 2002-08-07 | |
| PCT/US2003/024868 WO2004014306A2 (en) | 2002-08-07 | 2003-08-07 | Compositions and methods for the treatment of diseases exhibiting protein misassembly and aggregation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20051159L true NO20051159L (en) | 2005-04-26 |
Family
ID=31715805
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20051159A NO20051159L (en) | 2002-08-07 | 2005-03-04 | Preparations and Methods for the Treatment of Diseases That Incorrectly Assemble Protein Aggregation |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1575510A4 (en) |
| JP (1) | JP2006509726A (en) |
| KR (1) | KR20050053607A (en) |
| CN (1) | CN101123993A (en) |
| AU (1) | AU2003259073A1 (en) |
| CA (1) | CA2494908A1 (en) |
| IL (1) | IL166706A0 (en) |
| NO (1) | NO20051159L (en) |
| NZ (1) | NZ538145A (en) |
| WO (1) | WO2004014306A2 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2007139120A1 (en) * | 2006-05-30 | 2009-10-08 | 国立大学法人大阪大学 | Amyloid β clearance promoter |
| KR100982909B1 (en) * | 2009-07-08 | 2010-09-20 | 고려대학교 산학협력단 | Anti-cancer composition containing an ataxin-1 protein or a polynucleotide encoding ataxin-1 and a screening method of anti-cancer agents using the same |
| WO2011015572A1 (en) * | 2009-08-03 | 2011-02-10 | Galapagos Nv | Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases |
| US11492617B2 (en) | 2017-08-08 | 2022-11-08 | Ionis Pharmaceuticals, Inc | Compositions and methods for modulation of protein aggregation |
| WO2021078939A1 (en) | 2019-10-23 | 2021-04-29 | Universität Wien | Rna oligonucleotides for preventing aggregation of proteins |
| WO2023205579A1 (en) * | 2022-04-18 | 2023-10-26 | The Regents Of The University Of California | Compositions and methods for disrupting pathological aggregates |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU3495297A (en) * | 1996-07-08 | 1998-02-02 | Pioneer Hi-Bred International, Inc. | Transformation of zygote, egg or sperm cells and recovery of transformed plants from isolated embryo sacs |
| DE69842048D1 (en) * | 1997-08-01 | 2011-01-27 | Max Planck Gesellschaft | COMPOSITION AND METHOD FOR DETECTING DISEASES ASSOCIATED WITH THE FORMATION OF AMYLOID-SIMILAR FIBRILLES OR PROTEIN AGGREGATES |
| US7799535B1 (en) * | 1997-12-09 | 2010-09-21 | Arch Development Corporation | Methods for identifying factors that control the folding of amyloid proteins of diverse origin |
| EP1135113B1 (en) * | 1998-11-05 | 2008-10-01 | Thomas Jefferson University | Treatment of parkinson's disease with oligonucleotides |
| DE19925073C2 (en) * | 1999-06-01 | 2001-07-19 | Stefan Weiss | Nucleic acid molecules with specific recognition of native PrP · S ·· c ·, production and use |
| US6420122B1 (en) * | 1999-09-27 | 2002-07-16 | Massachusetts Institute Of Technology | Methods of screening for agents that inhibit aggregation of polypeptides |
| EP1366368A2 (en) * | 2001-01-03 | 2003-12-03 | Ortho-Mcneil Pharmaceutical, Inc. | Alpha synuclein aggregation assays |
| ATE532874T1 (en) * | 2001-02-15 | 2011-11-15 | Univ Chicago | METHOD FOR DETECTING IN YEAST FOR MEANS OF INFLUENCING PROTEIN FOLDING |
| US20030109476A1 (en) * | 2001-08-07 | 2003-06-12 | Kmiec Eric B. | Compositions and methods for the prevention and treatment of Huntington's disease |
| CA2468145A1 (en) * | 2001-11-21 | 2003-05-30 | Japan Science And Technology Agency | Transcriptional factors for the huntington's disease gene |
| US20030235823A1 (en) * | 2002-06-24 | 2003-12-25 | The University Of Alabama | Nucleotide sequences that code for torsin genes, torsin proteins, and methods of using the same to treat protein-aggregation |
-
2003
- 2003-08-07 CA CA002494908A patent/CA2494908A1/en not_active Abandoned
- 2003-08-07 KR KR1020057002251A patent/KR20050053607A/en not_active Ceased
- 2003-08-07 NZ NZ538145A patent/NZ538145A/en unknown
- 2003-08-07 AU AU2003259073A patent/AU2003259073A1/en not_active Abandoned
- 2003-08-07 JP JP2004527888A patent/JP2006509726A/en active Pending
- 2003-08-07 EP EP03785053A patent/EP1575510A4/en not_active Withdrawn
- 2003-08-07 WO PCT/US2003/024868 patent/WO2004014306A2/en not_active Ceased
- 2003-08-07 CN CNA038238969A patent/CN101123993A/en active Pending
-
2005
- 2005-02-06 IL IL16670605A patent/IL166706A0/en unknown
- 2005-03-04 NO NO20051159A patent/NO20051159L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2494908A1 (en) | 2004-02-19 |
| EP1575510A2 (en) | 2005-09-21 |
| JP2006509726A (en) | 2006-03-23 |
| IL166706A0 (en) | 2006-01-15 |
| CN101123993A (en) | 2008-02-13 |
| KR20050053607A (en) | 2005-06-08 |
| WO2004014306A2 (en) | 2004-02-19 |
| NZ538145A (en) | 2008-05-30 |
| AU2003259073A1 (en) | 2004-02-25 |
| EP1575510A4 (en) | 2007-12-26 |
| WO2004014306A3 (en) | 2006-05-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1116463T1 (en) | Combination therapy for the therapeutic treatment of Protein Deficiency Disorders | |
| NO20050807L (en) | Pharmaceutical compositions including dextromethorphan and quinidine for the treatment of neurological disorders | |
| LTPA2017009I1 (en) | Bruton tyrosine kinase inhibitors | |
| BR0315688A (en) | Compounds, pharmaceutical compositions and their uses in the treatment or prevention of diseases or conditions of metabolic cell proliferation | |
| EP2319925A3 (en) | Therapeutic uses of inhibitors of RTP801 | |
| WO2003096990A3 (en) | Protein cages for the delivery of medical imaging and therapy | |
| BRPI0407662B8 (en) | 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases | |
| WO2002040702A3 (en) | Methods for the treatment of cancer and other diseases and methods of developing the same | |
| DK1654253T3 (en) | Substituted 3-pyrrolidine indole derivatives | |
| CY1108932T1 (en) | Compounds 4- (heterocyclyl) -benzenesulfoximine for the therapeutic treatment of inflammatory diseases | |
| MXPA05012358A (en) | Pharmaceutical combination comprising modafinil and another drug. | |
| BR0310061A (en) | Methods for treating respiratory diseases and conditions with a selective inhibitor of inos and a inhibitor of pde and their compositions | |
| CY1109666T1 (en) | METHOD OF THERAPEUTIC AND RACOIDIS DISEASE TREATMENT | |
| NO20051159L (en) | Preparations and Methods for the Treatment of Diseases That Incorrectly Assemble Protein Aggregation | |
| ATE548048T1 (en) | ONCOMODULIN FOR THE TREATMENT OF NEUROLOGICAL DISEASES | |
| WO2003080800A3 (en) | Prevention and treatment of disease using angiogenesis-and/or tumor antigens | |
| NO20075508L (en) | Stable Soporphine Preparations and Administration | |
| IL175358A0 (en) | 1,4-dihydropyridine compounds, pharmaceutical compositions, and methods for the treatment of cardiovascular disease | |
| ATE482217T1 (en) | DITHIOLOPYRROLONE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | |
| ATE402147T1 (en) | 1,4-DIHYDROPYRIDINE COMPOUNDS, PHARMACEUTICAL COMPOUNDS, AND METHODS FOR TREATING CARDIOVASCULAR DISEASES | |
| WO2003066806A3 (en) | Therapeutic use of aziridino compounds | |
| ATE338560T1 (en) | PHARMACEUTICAL COMPOSITION FOR THE MEDICAL TREATMENT OF BENEFICIARY PROSTATE HYPERPLASIA, METHOD OF PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | |
| BRPI0410305A (en) | compositions of a selective benzenesulfonamide or methylsulfonylbenzene-based cyclooxygenase-2 inhibitor and a cholinergic agent for the treatment of blood flow reduction or central nervous system trauma | |
| TW200500073A (en) | Pharmaceutical composition comprising an indolopyrrolocarbazole derivative and use thereof | |
| UA92465C2 (en) | Therapeutic uses of inhibitors of rtp801 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |